NASH Drugs Market, 2015 - 2025: With A High Unmet Need; Nash Is Anticipated To Be A Multi-Billion Market
DUBLIN, Oct. 16, 2015 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/9xcfq6/nash_drugs) has announced the addition of the "NASH Drugs Market, 2015 - 2025" report to their offering.
The NASH Drugs Market, 2015-2025' report provides a comprehensive study on the current landscape and the future outlook of the evolving pipeline of molecules in this area. With an expanding NAFLD and NASH population worldwide, there is a growing need for development of therapeutics in this disease area.
NASH is gradually emerging as the leading cause of liver transplants. While the field has garnered interest of several companies, there are no approved therapies till date. It is important to stress that the development pipeline of NASH has several promising candidates that are likely to result in many commercial success stories in the foreseen future.
Amongst other elements, the report elaborates on the new diagnostic solutions being developed and the upcoming opportunities for different stakeholders. As pharmaceutical companies continue to initiate and expand their research programs in this area, one of the key objectives outlined for this report is to understand the future potential of the market.
This is done by analyzing:
- The epidemiology, patient population and staging of NASH in different geographies.
- The NASH pipeline in terms of phase of development, type of molecule, route of administration and mechanism of action.
- The likely evolution in the rate of diagnosis, drug treated patient population and the likely price of the drugs.
- The associated constraints, in terms of undefined pathogenesis and the unavailability of non-invasive diagnostic tests, and the initiatives being carried out by the companies to overcome these.
The study provides a detailed scenario analysis to estimate the market forecast for the period till 2025. The research, analysis and insights presented in this report include potential sales of the drugs in late stages of development and expected to launch by 2025. Our opinions and insights, presented in this study, were influenced by the discussions that we conducted with experts in this area. These included senior representatives at BiOrion Technologies, Phenex Pharmaceuticals, Tobira Therapeutics, Verlyx Pharmaceuticals and Connexios.
Key Topics Covered:
1. Preface
2. Executive Summary
3. Introduction
4. Treatment Options And Diagnostic Solutions
5. Market Dynamics
6. Market Overview
7. Upcoming Nash Drugs: Detailed Profiles
8. Market Sizing And Opportunity Analysis
9. Company Profiles
10. Conclusion
11. Interview Transcripts
12. Appendix1: Tabulated Data
13. Appendix 2: List Of Companies And Organizations
Companies Mentioned
- Alnylam Pharmaceuticals
- American Diabetes Association
- Arresto Biosciences
- AstraZeneca
- BiOrion Technologies
- BHV Pharma
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Cadila Healthcare
- Cerenis Therapeutics
- Conatus Pharmaceuticals
- Connexios
- DS Biopharma
- Durect
- Encode Pharmaceuticals
- Enanta Pharmaceuticals
- Endonovo Therapeutics
- Exalenz Bioscience
- Fournier
- Galectin Therapeutics
- Galmed Pharmaceuticals
- Genfit
- Gilead Sciences
- Idun
- Immune Pharmaceuticals
- ImmuNess
- Immuron Ltd.
- Intercept Pharmaceuticals
- Isis Pharmaceuticals
- Islet Sciences
- Johns Hopkins University
- Kadmon
- Kissei Pharmaceuticals
- KrisaniBio
- Kyorin Pharmaceutical
- LibbsFarmaceutica
- Ligand
- Madrigal Pharmaceuticals
- Matinas BioPharma
- McGill University
- Medicinova
- Merck
- Metabolic Solutions
- Mochida Pharmaceutical Company
- Naia Pharmaceuticals
- National Institute of Diabetes and Digestive and Kidney Diseases
- NAFLD Clinical Research Network
- Niigata University
- NGM Biopharmaceuticals
- Nimbus Therapeutics
- Novo Nordisk
- One Way Liver Genomics SL
- Perrigo API
- Pfizer
- Pierre Fabre
- Phenex Pharmaceuticals
- Raptor Pharmaceuticals
- Regulus Therapeutics
- Sanofi-Aventis
- SATT Sud Est
- Seattle Children's Research Institute
- Servier
- Shire
- Sumitomo Dainippon Pharma
- Taiwan Pharmaceuticals
- Therapix Biosciences
- Tobira Therapeutics
- University of Arizona
- University of California
- University of Perugia
- Verlyx Pharma
- Verva Pharmaceuticals
- Viking Therapeutics
- ViroBay
- XTuit Pharmaceuticals
- Zafgen
- Zydus Cadila
For more information visit http://www.researchandmarkets.com/research/9xcfq6/nash_drugs
Media Contact: Laura Wood , +353-1-481-1716, [email protected]
SOURCE Research and Markets
Share this article